The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•15 April 2026•

1 min read

Bristol Myers Squibb's Breyanzi Sales Projected to Top $1 Billion by 2025

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Breyanzi's sales run rate is expected to top $1 billion annually by 2025.

2The drug received FDA approval to expand across five different cancer indications.

Bristol Myers Squibb is seeing strong market momentum for its CAR T-cell therapy, Breyanzi, which is projected to reach a sales run rate of over $1 billion annually by 2025. This positive outlook follows recent FDA approvals that expanded the drug's use across five different cancer indications. The company is strategically positioning Breyanzi as a key growth driver to mitigate revenue losses caused by patent expirations and increasing competition from generic alternatives. The expanded regulatory approval is expected to significantly boost the drug's market penetration in the oncology sector. Analysts view this development as a critical step in the company's efforts to diversify its revenue streams. While generic competition remains a headwind, the blockbuster potential of Breyanzi provides a bullish signal for the firm's pharmaceutical portfolio.